COMMUNIQUÉS West-GlobeNewswire

Sanuwave Announces Q1 FY2025 Financial Results
09/05/2025
Q1 2025 revenues were $9.3 million , up 61% from $5.8 million in Q1 2024. This represents the highest Q1 quarterly revenues in Company history. Q1 2025 gross margin was 79.0% , versus 72.6% in Q1 2024. GAAP Operating [...]
Rectify Pharma Presents Translational Data for Novel Positive Functional Modulator Demonstrating Improved Biliary and Liver Health at EASL 2025
09/05/2025
Oral dual-targeted ABCB4/BSEP positive functional modulator (PFM) improved cholestatic and cholangitis markers in orthogonal models of hepatobiliary disease Data reinforce the potential of this differentiated mechanism [...]
Zealand Pharma announces closing of collaboration and license agreement with Roche
09/05/2025
Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: [...]
Invitation à assister à l'assemblée générale annuelle et extraordinaire des actionnaires de la Société qui se tiendra le 11 juin 2025
09/05/2025
INFORMATIONS RÉGLEMENTÉES le 9 mai 2025, 7:00h CET / 1:00h ET NYXOAH SA (Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgique (ci-après la « Société ») Invitation à assister à l' [...]
Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 11, 2025
09/05/2025
REGULATED INFORMATION May 9, 2025, 7:00am CET / 1:00am ET NYXOAH SA (Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (hereinafter the “ Company ”) Invitation to attend the annual and the [...]
Bavarian Nordic Announces Interim Results for the First Three Months of 2025
09/05/2025
COPENHAGEN, Denmark , May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. Revenue for the first three months increased by [...]
Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights
09/05/2025
SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq-CM: TSBX) , a biotechnology company historically focused on the development of a differentiated approach to [...]
Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
08/05/2025
Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML Additional safety and efficacy data including 6-month MMR expected in 4Q25 Phase 2 FALCON trial of TERN-601 for obesity is enrolling well with [...]
Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates
08/05/2025
Presented positive 4- and 12-week clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while [...]
Treace Medical Concepts Reports First Quarter 2025 Financial Results
08/05/2025
PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Cytek Biosciences Reports First Quarter 2025 Financial Results
08/05/2025
FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first [...]
Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance
08/05/2025
MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to [...]
Fulcrum Therapeutics to Participate in Upcoming May Conferences
08/05/2025
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
Senseonics Holdings, Inc. Reports First Quarter Financial Results
08/05/2025
Q1 Revenue of $6.3 million, growth year over year of 24% Partnership with Sequel integrates twiist ™ automated insulin delivery (AID) system with Eversense® 365 one-year continuous glucose monitor (CGM); twiist with [...]
Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results
08/05/2025
CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for [...]
Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
08/05/2025
Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025; Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025 Cash runway extending into the third quarter [...]
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update
08/05/2025
Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in [...]
Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
08/05/2025
Regulatory Interactions and Commercial, Medical, and Corporate Preparations On-Track for Paltusotine New Drug Application with September 25, 2025 PDUFA Date CALM-CAH Phase 3 Study of Atumelnant for the Treatment of [...]
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
08/05/2025
Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to date Initiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected in Q3 2025, [...]

Pages